Project Grant R21AI186023

Award Date 5/16/24
Completion Date 3/31/26
Dollars Obligated $960K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research aimed at understanding the mechanisms underlying mast cell expansion and function in human airway diseases, including asthma and nasal polyposis. The $715,968 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, will fund a 5-year project to investigate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $612,328 to National Jewish Health to conduct research investigating how the transcription factor MITF regulates mast cell lineage commitment and function. The research aims to enhance understanding of the regulation of mast cell genes that influence allergy susceptibility and severity. Specifically, the grant will...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $917,375 to Brigham & Women's Hospital Inc. to conduct research on defining the heterogeneous effector function of human mast cell subsets. The research aims to comprehensively characterize the cytokine, chemokine, and growth factor production profiles of in vitro-derived mast cell subtypes (MCT and...
This $2,016,357 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to characterize the role of transmembrane protein 178 (TMEM178) in bronchial epithelial cells and its impact on asthma pathogenesis. The key objectives are to: 1) investigate how TMEM178-mediated inhibition of calcium signaling is disrupted in asthmatic bronchial epithelial cells, 2) assess the effects of...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $462,501 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, to conduct research on mast cell activation as a common mechanism of pulmonary toxicity from chemical threat agents. The two-year project aims to examine how activation of mast cells contributes to lung inflammation and injury caused by exposure to various...
This Cooperative Agreement, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support comprehensive research on mapping airway epithelial cell-immune cell interactions in lung diseases like asthma and COPD. The primary awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will receive $798,062 over the 5-year project period from September 2024 to August 2029. The research...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to investigate the role of TGF-beta signaling in regulating T follicular helper (Tfh) cells and mast cell function, and how disruption of this pathway impacts allergic disease pathogenesis. The $162,000 award to the Trustees of Indiana University, Indianapolis will utilize a mouse model of Loeys-Dietz...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $586,250 to the University of Massachusetts Medical School (UMass Medical) to elucidate the pathways that lead to the differentiation of TFH13 cells, a novel T cell subset that drives the production of high-affinity, pathogenic IgE antibodies in allergic diseases. The overarching goal is to determine the distinct...
This $260,445 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify biomarkers associated with nasal polyp recurrence in patients with aspirin-exacerbated respiratory disease (AERD). The research aims to: 1) Establish a biomarker-based predictive model of nasal polyp recurrence in AERD patients based on tissue samples, using both type 2 and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $185,866 to the University of Vermont & State Agricultural College to investigate the role of airway epithelial syndecan-1 (SDC1) in a preclinical model of steroid-resistant severe allergic asthma. The key objectives are to evaluate the impact of macrophage-derived heparanase activity on SDC1 cleavage in...

GENETIC TARGETING OF INTRAEPITHELIAL MAST CELLS - PROJECT SUMMARY/ABSTRACT: MAST CELLS (MCS) EXPAND WITHIN THE AIRWAY EPITHELIUM DURING PREVALENT AND BURDENSOME HUMAN RESPIRATORY DISEASE, INCLUDING ASTHMA AND NASAL POLYPOSIS, WHERE THEY ARE THOUGHT TO PLAY A CENTRAL ROLE IN DISEASE PATHOBIOLOGY. THE EXPANDED INTRAEPITHELIAL MC COMPARTMENT CHARACTERISTIC OF TH2 HIGH ASTHMA CORRELATES WITH DISEASE SEVERITY AND THERAPEUTIC TARGETING OF THIS COMPARTMENT IMPROVES PATIENT OUTCOMES, SUGGESTING A CENTRAL ROLE IN DISEASE PATHOBIOLOGY. DESPITE THIS, THE MECHANISM(S) THROUGH WHICH INTRAEPITHELIAL MAST CELLS PARTICIPATE IN AIRWAY INFLAMMATION REMAIN UNCLEAR, IN PART DUE TO A LACK OF ROBUST PRE-CLINICAL MODELS TO SELECTIVELY TARGET THIS MC SUBSET IN AN IN-VIVO SETTING. THIS PROPOSAL DESCRIBES THE CREATION OF A NOVEL MOUSE STRAIN IN WHICH TAMOXIFEN-INDUCIBLE CRE RECOMBINASE COUPLED WITH A FLUORESCENT REPORTER TAG IS SELECTIVELY EXPRESSED WITHIN THE LUNG BY INFLAMMATION-EXPANDED INTRAEPITHELIAL MAST CELLS, TERMED MUCOSAL MAST CELLS (MMCS) IN MICE, AND WILL USE THIS STRAIN TO TEST THE HYPOTHESIS THAT INTRAEPITHELIAL MAST CELLS ARE AN IMPORTANT CONTRIBUTOR TO AIRWAY INFLAMMATORY DISEASE PROGRESSION. AIM 1 OF THIS STUDY WILL VALIDATE REPORTER CONSTRUCT RESTRICTION TO THE MMC LINEAGE ACROSS TISSUES AND CONDUCT A TIMECOURSE ANALYSIS OF THE DYNAMICS OF CONSTRUCT UPREGULATION AND ITS LONG-TERM MAINTENANCE WITHIN THE LUNG MMCS COMPARTMENT. AIM 2 WILL USE OUR STRAIN TO GENERATE INDUCIBLE MMC KNOCKOUT MICE, WHICH WILL THEN BE USED TO TEST THE DEGREE TO WHICH MMC REGULATE PULMONARY INFLAMMATION AND AIRWAY HYPERREACTIVITY AT TWO DISCRETE PHASES OF ALLERGIC LUNG INFLAMMATION. COMPLETION OF THESE AIMS WILL PROVIDE DEFINITIVE EVIDENCE AS TO THE IMPORTANCE OF MMC IN ALLERGIC LUNG INFLAMMATION AND SET THE STAGE FOR FUTURE STUDIES USING THIS STRAIN TO BOTH DETERMINE THE MECHANISM(S) THROUGH WHICH THEY INFLUENCE LUNG INFLAMMATION AND TEST THEIR IMPORTANCE IN OTHER MODELS OF MUCOSAL INFLAMMATION, SUCH AS FOOD ALLERGY AND EOSINOPHILIC ESOPHAGITIS.

Posted 5/16/24, 12:00 AM